EvolusEOLS -0.21%71 FCF Yield % is -9.56 as of Jun. 27, 2026. GuruFocus rates EOLS with a GF Score™ of 71/100 and a GF Value™ of $13.60 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Evolus ranks worse than 80.3% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Evolus's Trailing 12-Month Free Cash Flow is $-44.9 Mil, and Market Cap is $469.5 Mil. Therefore, Evolus's FCF Yield % for today is -9.56%.
The historical rank and industry rank for Evolus's FCF Yield % or its related term are showing as below:
EOLS'
s FCF Yield % Range Over the Past 10 Years
Min: -87.78 Med: -11.88 Max: -1.5
Current: -9.56
During the past 11 years, the highest FCF Yield % of Evolus was -1.50%. The lowest was -87.78%. And the median was -11.88%.
EOLS's FCF Yield % is ranked worse than 80.3% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 0.67
vs EOLS: -9.56
Evolus's FCF Margin % for the quarter that ended in Mar. 2026 was -15.92%.
Evolus FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Evolus FCF Yield % Related Terms
Evolus FCF Yield % Historical Data
* Premium members only.
The historical data trend for Evolus's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Evolus's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evolus FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evolus's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Evolus's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evolus (EOLS) has a FCF Yield % of -9.56 as of Jun. 27, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Evolus and its competitors. According to the industry distribution chart, Evolus ranks #807 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 80.3%.
Is Evolus' FCF Yield % too high?
Evolus' current FCF Yield % is -9.56. Based on the distribution chart, Evolus ranks #807 out of 1005 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Evolus has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evolus' FCF Yield % compare to EBS and ELTP?
According to the Drug Manufacturers industry distribution chart, Evolus ranks #807 out of 1005 companies for FCF Yield %. This places Evolus in the lower half of its industry. The industry median FCF Yield % is 0.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.67, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Evolus and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evolus's current FCF Yield % is -9.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolus stock overvalued right now?
Based on GuruFocus' analysis, Evolus (EOLS) is currently considered Possible Value Trap. The stock's GF Value™ is $13.60, compared to a current price of $7.13 — trading 47.6% below its estimated fair value. The current FCF Yield % is -9.56. Evolus' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Evolus (EOLS), the current FCF Yield % is -9.56 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evolus (EOLS) Overvalued in 2026?
Based on GuruFocus' analysis, Evolus stock appears to be undervalued.
The current stock price of $7.13 is trading 47.6% below its estimated GF Value™ of $13.60.
GuruFocus considers Evolus to be Possible Value Trap.
Key valuation signals for EOLS:
FCF Yield %: -9.56
GF Value™: $13.60 vs. price of $7.13 (47.6% below fair value)
No single metric tells the full story. See the EOLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
71GF Score
Get the complete analysis for EOLS
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EOLS has been successfully added to your 
